Filtered By:
Vaccination: Pneomococcal Vaccine

This page shows you your search results in order of relevance. This is page number 6.

Order by Relevance | Date

Total 3041 results found since Jan 2013.

Pneumococcal Vaccination in Rheumatology: Utilizing Nurse-Driven Protocol For Pneumococcal Vaccination in an Academic Rheumatology Clinic
CONCLUSION: It is feasible to employ a nurse-driven protocol for improving pneumococcal vaccination rates in immunosuppressed patients, despite difficulties posed by COVID-19 pandemic disruptions.PMID:36319017 | DOI:10.3899/jrheum.220771
Source: J Rheumatol - November 1, 2022 Category: Rheumatology Authors: Elena K Joerns Nagendra Pokala Bonnie Bermas Joan Reisch Dan Clarie Wang Reuben Arasaratnam Puneet Bajaj Source Type: research

Pneumococcal Vaccination in Adults: What Can We Learn From Observational Studies That Evaluated PCV13 and PPV23 Effectiveness in the Same Population?
CONCLUSIONS: Overall, PCV13 demonstrated better protection than PPV23 against pneumococcal disease and all-cause respiratory outcomes in the included studies. Where evaluated, sequential PCV13/PPV23 vaccination showed little benefit over PCV13 alone. Results support the use of PCVs to protect against pneumococcal disease and respiratory infections in adults.PMID:36681604 | DOI:10.1016/j.arbres.2022.12.015
Source: Archivos de Bronconeumologia - January 21, 2023 Category: Respiratory Medicine Authors: Eileen M Dunne Catia Cilloniz Claire von Mollendorf Joseph Lewnard Lindsay R Grant Mary P E Slack Luis Jodar Christian Theilacker Bradford D Gessner Source Type: research

Accounting for Adverse Events Following Immunization in Economic Evaluation: Systematic Review of Economic Evaluations of Pediatric Vaccines Against Pneumococcus, Rotavirus, Human Papillomavirus, Meningococcus and Measles-Mumps-Rubella-Varicella
DiscussionAlthough (mild) AEFI were demonstrated for all five studied vaccines, only a quarter of reviewed studies accounted for these, mostly in an incomplete and inaccurate manner. We provide guidance on which methods to use to better quantify the impact of AEFI on both costs and health outcomes. Policymakers should be aware that the impact of AEFI on cost-effectiveness is likely to be underestimated in the majority of economic evaluations.
Source: PharmacoEconomics - February 21, 2023 Category: Health Management Source Type: research